1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > Other Central Nervous System Disorders - Pipeline Review, H2 2013

Other Central Nervous System Disorders - Pipeline Review, H2 2013

  • October 2013
  • -
  • Global Markets Direct
  • -
  • 45 pages

Other Central Nervous System Disorders - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Other Central Nervous System Disorders - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Other Central Nervous System Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Other Central Nervous System Disorders. Other Central Nervous System Disorders - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Other Central Nervous System Disorders.
- A review of the Other Central Nervous System Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Other Central Nervous System Disorders pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Other Central Nervous System Disorders.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Other Central Nervous System Disorders pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Other Central Nervous System Disorders - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Other Central Nervous System Disorders Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Other Central Nervous System Disorders 7
Other Central Nervous System Disorders Therapeutics under Development by Companies 9
Other Central Nervous System Disorders Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Discovery and Pre-Clinical Stage Products 14
Comparative Analysis 14
Other Central Nervous System Disorders Therapeutics - Products under Development by Companies 15
Other Central Nervous System Disorders Therapeutics - Products under Investigation by Universities/Institutes 16
Companies Involved in Other Central Nervous System Disorders Therapeutics Development 17
Quark Pharmaceuticals, Inc. 17
Vernalis plc 18
OPKO Health, Inc. 19
Newron Pharmaceuticals S.p.A. 20
M et P Pharma AG 21
Other Central Nervous System Disorders - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
progesterone - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
Neuroprotection And Neural Regeneration Program - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
HF-1220 - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
mecasermin - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
rifampin - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
Oligonucleotide For Rett Syndrome - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
Protein Fractions - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
Other Central Nervous System Disorders Therapeutics - Drug Profile Updates 34
Other Central Nervous System Disorders Therapeutics - Discontinued Products 35
Other Central Nervous System Disorders Therapeutics - Dormant Products 36
Other Central Nervous System Disorders - Product Development Milestones 37
Featured News and Press Releases 37
Nov 29, 2010: Takeda Applies For Change Of Dosage And Administration Of Leuplin For Treatment Of Central Precocious Puberty 37
Oct 29, 2010: AVANIR Receives FDA Approval For NUEDEXTA For Treatment Of Pseudobulbar Affect 37
Oct 19, 2010: MediciNova's Announces That MN-166 Program Recognized As One Of Windhover's Top 10 Neuroscience Projects To Watch 38
Sep 08, 2010: Hemispherx To Present New Retrovirus Data At First International Workshop On XMRV And Chronic Fatigue Syndrome 38
Jun 30, 2010: Oxygen Biotherapeutics' Oxycyte PFCE Decreases Mortality From Decompression Sickness In Preclinical Study 39
Jun 29, 2010: Alnylam Obtains Approval To Initiate Phase I Study With ALN-TTR01 In Patients With TTR-Mediated Amyloidosis 39
Jun 21, 2010: Sinapis Pharma Commences Phase I Trial Of Methamphetamine In Brain Injury And Stroke Patients 40
May 26, 2010: EpiCept Achieves Targeted Patient Enrollment In Phase IIb Trial Of Epicept NP-1 For Treatment Of CPN 41
Apr 19, 2010: Prana Announces Publication Of New Analysis Of Clinical Trial In Journal Of Alzheimer's Disease 41
Apr 01, 2010: The Clinical Potential And Therapeutic Differentiation Of MediciNova's MN-166 Featured In Neurology Articles 42
Appendix 44
Methodology 44
Coverage 44
Secondary Research 44
Primary Research 44
Expert Panel Validation 44
Contact Us 45
Disclaimer 45



List of Tables

Number of Products Under Development for Other Central Nervous System Disorders, H2 2013 7
Products under Development for Other Central Nervous System Disorders - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Number of Products under Investigation by Universities/Institutes, H2 2013 10
Comparative Analysis by Late Stage Development, H2 2013 11
Comparative Analysis by Mid Clinical Stage Development, H2 2013 12
Comparative Analysis by Early Clinical Stage Development, H2 2013 13
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 14
Products under Development by Companies, H2 2013 15
Products under Investigation by Universities/Institutes, H2 2013 16
Quark Pharmaceuticals, Inc., H2 2013 17
Vernalis plc, H2 2013 18
OPKO Health, Inc., H2 2013 19
Newron Pharmaceuticals S.p.A., H2 2013 20
M et P Pharma AG, H2 2013 21
Assessment by Monotherapy Products, H2 2013 22
Assessment by Stage and Route of Administration, H2 2013 24
Assessment by Stage and Molecule Type, H2 2013 26
Other Central Nervous System Disorders Therapeutics - Drug Profile Updates 34
Other Central Nervous System Disorders Therapeutics - Discontinued Products 35
Other Central Nervous System Disorders Therapeutics - Dormant Products 36



List of Figures

Number of Products under Development for Other Central Nervous System Disorders, H2 2013 7
Products under Development for Other Central Nervous System Disorders - Comparative Analysis, H2 2013 8
Products under Development by Companies, H2 2013 9
Products under Investigation by Universities/Institutes, H2 2013 10
Late Stage Products, H2 2013 11
Mid Clinical Stage Products, H2 2013 12
Early Clinical Stage Products, H2 2013 13
Discovery and Pre-Clinical Stage Products, H2 2013 14
Assessment by Monotherapy Products, H2 2013 22
Assessment by Route of Administration, H2 2013 23
Assessment by Stage and Route of Administration, H2 2013 24
Assessment by Molecule Type, H2 2013 25
Assessment by Stage and Molecule Type, H2 2013 26



Companies Mentioned

Quark Pharmaceuticals, Inc.
Vernalis plc
OPKO Health, Inc.
Newron Pharmaceuticals S.p.A.
M et P Pharma AG

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Pipeline Review, H2 2016

Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Neuronal Acetylcholine Receptor Subunit Beta 2 (CHRNB2) - Pipeline Review, H2 2016’, ...

Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Pipeline Review, H2 2016

Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Leucine Rich Repeat Serine/Threonine Protein Kinase 2 (Dardarin or LRRK2 or EC 2.7.11.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Leucine Rich Repeat Serine/Threonine Protein Kinase ...

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, H2 2016

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Metabotropic Glutamate Receptor 3 (GPRC1C or MGLUR3 or GRM3) - Pipeline Review, ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.